Skip to Main Content

Author Details

Marcus Bosenberg
Yale School of Medicine
1992
223
67
Trey Ideker (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37872018GNAQ-mutated primary subcutaneous blue melanoma arising in naevus of Ota presenting as a skin-coloured forehead mass.Pathology2024
36630138Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions: A Consensus Statement.JAMA Netw Open2023
37964379A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better.Mol Cancer2023
37733872Manipulating mitochondrial electron flow enhances tumor immunogenicity.Science2023
37459511IL-7R licenses a population of epigenetically poised memory CD8<sup>+</sup> T cells with superior antitumor efficacy that are critical for melanoma memory.Proc Natl Acad Sci U S A2023
37352855Cooperative sensing of mitochondrial DNA by ZBP1 and cGAS promotes cardiotoxicity.Cell2023
37087398Mouse models for immuno-oncology.Trends Cancer2023
37086630Discovery of decreased ferroptosis in male colorectal cancer patients with KRAS mutations.Redox Biol2023
37382208Determinants of overall survival in patients with metastatic uveal melanoma.Cancer2023
37478171Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance.Cancer Immunol Res2023
37292991<i>Setdb1</i> -loss induces type-I interferons and immune clearance of melanoma.bioRxiv2023
36449280The Crossroads of Cancer Epigenetics and Immune Checkpoint Therapy.Clin Cancer Res2023
36881866Type 2 Dendritic Cells Orchestrate a Local Immune Circuit to Confer Antimetastatic Immunity.J Immunol2023
36739981Validation of the Prognostic Usefulness of the Gene Expression Profiling Test in Patients with Uveal Melanoma.Ophthalmology2023
36909561Discovery of decreased ferroptosis in male colorectal cancer patients with KRAS mutations.bioRxiv2023
36573964Targeting ULK1 Decreases IFNγ-Mediated Resistance to Immune Checkpoint Inhibitors.Mol Cancer Res2023
36703079Ferroptosis in colorectal cancer: a future target?Br J Cancer2023
36824269PTEN phosphatase inhibits metastasis by negatively regulating the Entpd5/IGF1R pathway through ATF6.iScience2023
34407291The role of ferroptosis in melanoma.Pigment Cell Melanoma Res2022
35737114Coupled fibromodulin and SOX2 signaling as a critical regulator of metastatic outgrowth in melanoma.Cell Mol Life Sci2022
35668129Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis.Nat Commun2022
35598954Corrigendum to "Physachenolide C induces complete regression of established murine melanoma tumors via apoptosis and cell cycle arrest".Transl Oncol2022
36514045Longitudinal single-cell analysis of a patient receiving adoptive cell therapy reveals potential mechanisms of treatment failure.Mol Cancer2022
36457136Isotope tracing reveals distinct substrate preference in murine melanoma subtypes with differing anti-tumor immunity.Cancer Metab2022
35912544Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.Pigment Cell Melanoma Res2022
35876628Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study.Pigment Cell Melanoma Res2022
35316223Tim-3 mediates T cell trogocytosis to limit antitumor immunity.J Clin Invest2022
35219026Inhibition of renalase drives tumour rejection by promoting T cell activation.Eur J Cancer2022
34735896Physachenolide C induces complete regression of established murine melanoma tumors via apoptosis and cell cycle arrest.Transl Oncol2022
32895985Discordant anti-SARS-CoV-2 spike protein and RNA staining in cutaneous perniotic lesions suggests endothelial deposition of cleaved spike protein.J Cutan Pathol2021
33602823Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation.Proc Natl Acad Sci U S A2021
33545064Melanoma models for the next generation of therapies.Cancer Cell2021
33813761HPyV6- and HPyV7-negative parakeratosis and dyskeratosis in squamous cell carcinoma in situ.J Cutan Pathol2021
336155175-Fluorouracil efficacy requires anti-tumor immunity triggered by cancer-cell-intrinsic STING.EMBO J2021
33500588Publisher Correction: VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours.Nature2021
35121870Publisher Correction: Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response.Nat Cancer2021
34909719Cytokine RNA In Situ Hybridization Permits Individualized Molecular Phenotyping in Biopsies of Psoriasis and Atopic Dermatitis.JID Innov2021
34671158KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements.Nature2021
345728073D Model of the Early Melanoma Microenvironment Captures Macrophage Transition into a Tumor-Promoting Phenotype.Cancers (Basel)2021
34416167Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.Cancer Cell2021
33936449Validation of the Data Quality of a Tumor Board Registry Through Assessment of Clinicopathologic Survival Outcomes in Melanoma Patients.AMIA Annu Symp Proc2021
34140403A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1.Clin Cancer Res2021
33945506The deacylase SIRT5 supports melanoma viability by influencing chromatin dynamics.J Clin Invest2021
33317858Treatment of granuloma annulare and suppression of proinflammatory cytokine activity with tofacitinib.J Allergy Clin Immunol2021
32566387Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer.Oncoimmunology2020
34476408Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response.Nat Cancer2020
31769872PLEKHA5 regulates tumor growth in metastatic melanoma.Cancer2020
31855437Tumor-Targeted, Cytoplasmic Delivery of Large, Polar Molecules Using a pH-Low Insertion Peptide.Mol Pharm2020
31942068VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours.Nature2020
31911617Siah2 control of T-regulatory cells limits anti-tumor immunity.Nat Commun2020
  • 1 - 50 of 223

Recommended Authors

Andrew McNeal
University of California San Francisco
Career Start Year 2014
Number of shared co-authors 1
Shruthy Suresh
Memorial Sloan Kettering Cancer Center
Career Start Year 2013
Number of shared co-authors 3
Manoela Tiago
Thomas Jefferson University
Career Start Year 2011
Number of shared co-authors 7
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 7
Olivia M Lucero
Oregon Health & Science University
Career Start Year 2009
Number of shared co-authors 0
Vijay Walia
National Center for Toxicological Research
Career Start Year 2006
Number of shared co-authors 6
Shadmehr Demehri
Massachusetts General Hospital and Harvard Medical School
Career Start Year 2004
Number of shared co-authors 3
Chi-Ping Day
Center for Cancer Research, National Cancer Institute
Career Start Year 2002
Number of shared co-authors 17
Susan L Woods
Adelaide Medical School, University of Adelaide
Career Start Year 2002
Number of shared co-authors 5
Daniel Zingg
Netherlands Cancer Institute
Career Start Year 2001
Number of shared co-authors 5
Marcory C R F van Dijk
1Rijnstate Hospital
Career Start Year 2001
Number of shared co-authors 0
Beate Rinner
Medical University of Graz
Career Start Year 2000
Number of shared co-authors 2
Todd D Prickett
National Cancer Institute
Career Start Year 2000
Number of shared co-authors 14
David J Liewehr
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 3
Christopher J Howlett
Western University
Career Start Year 1999
Number of shared co-authors 0
Bartosz Chmielowski
Jonsson Comprehensive Cancer Center, University of California Los Angeles
Career Start Year 1999
Number of shared co-authors 9
Travis J Hollmann
Memorial Sloan Kettering Cancer Center
Career Start Year 1998
Number of shared co-authors 13
Hae-Ock Lee
College of Medicine, The Catholic University of Korea
Career Start Year 1996
Number of shared co-authors 0
Timothy A Chan
Cleveland Clinic.
Career Start Year 1994
Number of shared co-authors 10
Richard W Joseph
Mayo Clinic Hospital
Career Start Year 1994
Number of shared co-authors 9
Craig Gedye
Hunter Medical Research Institute, University of Newcastle
Career Start Year 1993
Number of shared co-authors 1
Jan Paul Medema
Oncode Institute
Career Start Year 1993
Number of shared co-authors 4
Levi A Garraway
Broad Institute of Harvard and MIT
Career Start Year 1991
Number of shared co-authors 29
Roger Chammas
Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina de Sao Paulo
Career Start Year 1989
Number of shared co-authors 0
Thomas J Hornyak
University of Maryland School of Medicine
Career Start Year 1989
Number of shared co-authors 5
Daniel S Peeper
Netherlands Cancer Institute
Career Start Year 1987
Number of shared co-authors 13
Louis Gaboury
Institute for Research in Immunology and Cancer (IRIC), University of Montreal
Career Start Year 1986
Number of shared co-authors 1
Jonathan Cebon
Australia Olivia Newton-John Cancer Research Institute, La Trobe University
Career Start Year 1985
Number of shared co-authors 10
Colin R Goding
Ludwig Institute for Cancer Research, University of Oxford
Career Start Year 1983
Number of shared co-authors 13
Menashe Bar-Eli
The University of Texas MD Anderson Cancer Center
Career Start Year 1975
Number of shared co-authors 12

Collaborators

Harriet M Kluger
Yale School of Medicine
Co-authored papers 18
Lynda Chin
Co-authored papers 14
Heinz Arnheiter
National Institute of Neurological Disorders and Stroke, National Institute of Health
Co-authored papers 13
Ze'ev Ronai
Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Co-authored papers 10
Andrew E Aplin
Thomas Jefferson University
Co-authored papers 8
Michael A Davies
The University of Texas MD Anderson Cancer Center
Co-authored papers 8
David P Curley
The Warren Alpert Medical School of Brown University
Co-authored papers 8
Akiko Iwasaki
Yale University
Co-authored papers 7
Antoni Ribas
University of California Los Angeles (university of california los angeles)
Co-authored papers 7
Yuval Kluger
Yale University School of Medicine
Co-authored papers 7
Eric Lau
Moffitt Cancer Center
Co-authored papers 6
Marzia Scortegagna
NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Co-authored papers 6
David E Fisher
Cutaneous Biology Research Center, Mass. General Hospital, Harvard Medical School
Co-authored papers 6
Jennifer A Wargo
Co-authored papers 6
Ashani T Weeraratna
Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine
Co-authored papers 6
Yongmei Feng
Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Co-authored papers 6
Richard A Scolyer
Co-authored papers 5
Georgina V Long
Co-authored papers 5
Glenn Merlino
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 5
Meenhard Herlyn
Ellen and Ronald Caplan Cancer Center, The Wistar Institute
Co-authored papers 5
Eric Song
Yale University
Co-authored papers 5
David L Rimm
Yale University School of Medicine
Co-authored papers 4
Joshua D Rabinowitz
Lewis Sigler Institute for Integrative Genomics, Princeton University
Co-authored papers 4
Gerald S Shadel
Salk Institute for Biological Studies
Co-authored papers 4
Reinhard Dummer
University Hospital Zurich
Co-authored papers 3
Phil F Cheng
University Hospital of Zurich
Co-authored papers 3
John M Kirkwood
UPMC Hillman Cancer Center
Co-authored papers 3
Nabeel Bardeesy
Massachusetts General Hospital
Co-authored papers 3
Tianyang Mao
Yale University School of Medicine
Co-authored papers 3
Lionel Larue
Institut Curie, PSL Research University, INSERM U1021
Co-authored papers 3
Release 1.2